Financing co-led by Norwest and SV Health Investors’ MedTech Convergence Fund will fund launch of Nanopath’s FDA 510(k) study for its point-of-care vaginitis test in support of potential expansion of its pipeline into UTIs and STIs, and build-out of its team ahead of proposed commercialization
CAMBRIDGE, Mass., Nov. 10, 2026 — Nanopath, a point-of-care diagnostics company enabling laboratory-quality molecular testing in minutes, today announced the close of a $25 million Series B financing round, which includes $2 million in non-dilutive grant financing. The round is co-led by Norwest and SV Health Investors’ MedTech Convergence Fund, alongside strategic participation from the Labcorp Venture Fund. New and existing investors also participated, including Elderberry Ventures, GingerBread Capital, and Alumni Ventures.
As part of the financing, Catherine Kiani, J.D., Managing Partner at Elderberry Ventures, and Mindy Nye, Ph.D., Vice President, Labcorp Diagnostics, have joined the Nanopath Board as Observers.
“Nanopath is developing truly transformative technology with the potential to reshape the molecular diagnostics industry and dramatically improve patient outcomes,” said Jeff Crowe, Senior Managing Partner at Norwest. “We are beyond excited to continue supporting the company at this key inflection point.”
Nanopath has developed the first clinical diagnostics platform built on plasmonic biosensing. The company’s proprietary optical biosensing technology is designed to enable molecular detection without nucleic acid amplification, a step required by PCR-based tests. “We’ve spent years developing and pressure-testing a fundamentally new approach to molecular diagnostics for patients who have been overlooked for far too long,” said Alison Burklund, Ph.D., Co-Founder & Co-CEO of Nanopath. “This funding brings us closer to the next and most important step – translating that innovation into meaningful clinical impact.”
The funding will support key milestones toward the potential commercial launch of Nanopath’s 15-minute point-of-care vaginitis assay, including manufacturing scale-up and initiation of Nanopath’s Food and Drug Administration 510(k) clinical study. Nanopath will also use the funding to expand its team across clinical and commercial functions as it prepares for launch. “We’re incredibly proud of the extraordinary team we’ve built at Nanopath and our shared commitment to transforming women’s healthcare,” said Amogha Tadimety, Ph.D., Co-Founder & Co-CEO of Nanopath. “We’re grateful for the confidence of our investors and excited to build on this momentum as we enter our next phase of growth.”
By delivering accurate results during a single visit, Nanopath aims to establish a new standard of care for women’s health and expand access to high-quality diagnostics for women across the United States. Over time, the platform is expected to expand to other clinical indications, improving healthcare by making sophisticated diagnostics more accessible at the point of care.
The vaginitis test is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration. Commercial availability is subject to successful completion of development activities and applicable regulatory review.
About Nanopath
Nanopath is a women-led company dedicated to improving health equity worldwide, starting with women’s health. Nanopath’s proprietary molecular diagnostic testing platform takes a radically new approach to how clinicians characterize human health. The company’s novel biosensing technology has the potential to enable fast, high-complexity testing at the point-of-care, rather than in centralized laboratories. The company is headquartered in Cambridge, Mass., at The Engine built by MIT, a premier facility for high-potential, tough-tech start-ups. Founded in 2020, Nanopath has raised more than $46 million, and is backed by Norwest, the Medtech Convergence Fund, an SV Health Investors Fund, Elderberry Ventures, GingerBread Capital, Alumni Ventures and the Labcorp Venture Fund. For more information, visit www.nanopath.com.
SOURCE Nanopath
